Xiao Xu

13.2k total citations · 1 hit paper
354 papers, 8.5k citations indexed

About

Xiao Xu is a scholar working on Molecular Biology, Hepatology and Surgery. According to data from OpenAlex, Xiao Xu has authored 354 papers receiving a total of 8.5k indexed citations (citations by other indexed papers that have themselves been cited), including 134 papers in Molecular Biology, 124 papers in Hepatology and 116 papers in Surgery. Recurrent topics in Xiao Xu's work include Organ Transplantation Techniques and Outcomes (77 papers), Liver Disease and Transplantation (58 papers) and Hepatocellular Carcinoma Treatment and Prognosis (57 papers). Xiao Xu is often cited by papers focused on Organ Transplantation Techniques and Outcomes (77 papers), Liver Disease and Transplantation (58 papers) and Hepatocellular Carcinoma Treatment and Prognosis (57 papers). Xiao Xu collaborates with scholars based in China, Madagascar and United States. Xiao Xu's co-authors include Shusen Zheng, Di Lu, Jianguo Wang, Haiyang Xie, Xuyong Wei, Xiaonan Xiang, Lin Zhou, Qi Ling, Zhikun Liu and Shusen Zheng and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Advanced Materials and Angewandte Chemie International Edition.

In The Last Decade

Xiao Xu

332 papers receiving 8.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting tumor-associated macrophages to synergize tumor immunotherapy

2021 656 citations Xiaonan Xiang, Jianguo Wang et al. profile →

Peers

Xiao Xu

MB

ONCOL

HEPAT

SURGE

CR

Lin Zhou China

Hirohisa Yano Japan

Lixin Wei China

Xuehao Wang China

Hongming Pan China

Toru Beppu Japan

John M. Luk Hong Kong

Haiyang Xie China

Diana Julie Leeming Denmark

Markus Guba Germany

Lin Zhou China

Xiao Xu

4.6k ×1.2

MB

2.0k ×1.2

ONCOL

1.4k ×0.8

HEPAT

1.5k ×0.9

SURGE

1.9k ×1.3

CR

Citations per year, relative to Xiao Xu Xiao Xu (= 1×) peers Lin Zhou

Countries citing papers authored by Xiao Xu

Since Specialization

Citations

This map shows the geographic impact of Xiao Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiao Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiao Xu more than expected).

Fields of papers citing papers by Xiao Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiao Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiao Xu. The network helps show where Xiao Xu may publish in the future.

Co-authorship network of co-authors of Xiao Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Xiao Xu. A scholar is included among the top collaborators of Xiao Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiao Xu. Xiao Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Guo, Haijun, Lijun Meng, Xuanyu Zhang, et al.. (2024). Oncogenic cholesterol rewires lipid metabolism in hepatocellular carcinoma via the CSNK2A1-IGF2R Ser2484 axis. Journal of Advanced Research. 76. 449–465. 4 indexed citations

2.

Xu, Xiao, et al.. (2024). Genetic engineering drives the breakthrough of pig models in liver disease research. Liver Research. 8(3). 131–140. 6 indexed citations

3.

Shen, Fuzhi, et al.. (2024). AuNPs/DNAzyme/siRNA three-dimensional nanomotor for CEACAM6 RNA detection in cerebrospinal fluid and gene therapy of NSCLC. Chemical Engineering Journal. 495. 153728–153728. 3 indexed citations

4.

Chen, Huan, et al.. (2024). MATR3 promotes liver cancer progression by suppressing DHX58–mediated type I interferon response. Cancer Letters. 604. 217231–217231. 4 indexed citations

5.

Xiang, Xiaonan, Kai Wang, Hui Zhang, et al.. (2024). Blocking CX3CR1+ Tumor-Associated Macrophages Enhances the Efficacy of Anti-PD1 Therapy in Hepatocellular Carcinoma. Cancer Immunology Research. 12(11). 1603–1620. 10 indexed citations

6.

Lu, Di, Abid Khan, Qingguo Xu, et al.. (2024). Myosteatosis and muscle loss impact liver transplant outcomes in male patients with hepatocellular carcinoma. Journal of Cachexia Sarcopenia and Muscle. 15(5). 2071–2083. 6 indexed citations

7.

Zhang, Hui, et al.. (2024). ZIP4 inhibits Ephrin-B1 ubiquitination, activating Wnt5A/JNK/ZEB1 to promote liver cancer metastasis. Genes & Diseases. 11(6). 101312–101312.

8.

Wang, Shuai, Lijun Meng, Huan Chen, et al.. (2024). Hepatocellular carcinoma-specific epigenetic checkpoints bidirectionally regulate the antitumor immunity of CD4 + T cells. Cellular and Molecular Immunology. 21(11). 1296–1308. 5 indexed citations

9.

Zhang, Hui, Jianguo Wang, Xiaonan Xiang, et al.. (2024). An Esterase-Responsive SLC7A11 shRNA Delivery System Induced Ferroptosis and Suppressed Hepatocellular Carcinoma Progression. Pharmaceutics. 16(2). 249–249. 5 indexed citations

10.

Wang, Shuai, Jianguo Wang, Yiyuan Chen, et al.. (2023). BMI1-induced CD127+KLRG1+ memory T cells enhance the efficacy of liver cancer immunotherapy. Cancer Letters. 571. 216336–216336. 12 indexed citations

11.

Zhang, Runnan, Shiqun Shao, Ying Piao, et al.. (2023). Esterase‐Labile Quaternium Lipidoid Enabling Improved mRNA‐LNP Stability and Spleen‐Selective mRNA Transfection. Advanced Materials. 35(46). e2303614–e2303614. 46 indexed citations

12.

Zhuo, Jianyong, Yiyuan Chen, Huan Chen, et al.. (2023). Downregulation of N4-acetylcytidine modification in myeloid cells attenuates immunotherapy and exacerbates hepatocellular carcinoma progression. British Journal of Cancer. 130(2). 201–212. 7 indexed citations

13.

Wang, Shuai, Rui Wang, Xuyong Wei, et al.. (2023). SULT2B1-CS-DOCK2 axis regulates effector T-cell exhaustion in HCC microenvironment. Hepatology. 78(4). 1064–1078. 33 indexed citations

14.

Wei, Qiang, Xiaodong Wang, Jun Chen, et al.. (2022). Preventive use of low molecular weight heparin in portal vein system thrombosis after splenectomy without portal hypertension. Heliyon. 8(12). e12482–e12482.

15.

Liu, Yan, Zhen-Zhe Li, Jixing Zhang, et al.. (2021). Circular RNA circHECTD1 facilitates glioma progression by regulating the miR‐296‐3p/SLC10A7 axis. Journal of Cellular Physiology. 236(8). 5953–5965. 10 indexed citations

16.

Wu, Yichao, Zhikun Liu, & Xiao Xu. (2020). Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine. Cancer Communications. 40(12). 681–693. 44 indexed citations

17.

Wang, Hangxiang, Zhongjie Lu, Lijiang Wang, et al.. (2017). New Generation Nanomedicines Constructed from Self-Assembling Small-Molecule Prodrugs Alleviate Cancer Drug Toxicity. Cancer Research. 77(24). 6963–6974. 133 indexed citations

18.

Xu, Xiao, Wanhong Xu, Wei Tang, et al.. (2016). AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients. Molecular Cancer Therapeutics. 15(11). 2586–2597. 69 indexed citations

19.

Xu, Xiao, et al.. (2012). DLK1 as a Potential Target against Cancer Stem/Progenitor Cells of Hepatocellular Carcinoma. Molecular Cancer Therapeutics. 11(3). 629–638. 75 indexed citations

20.

Xu, Xiao, et al.. (1995). Increased expression of cytokeratins CK8 and CK19 is associated with head and neck carcinogenesis.. PubMed. 4(8). 871–6. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact